Comparison · NCT04317040-c31e40f2
CD24Fc vs Placebo: Number of Participants Who Experience an Adverse Event (AE)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. CD24Fc vs Placebo: Number of Participants Who Experience an Adverse Event (AE). Trial comparisons, record NCT04317040-c31e40f2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04317040-c31e40f2
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.281 | 0.206 | 0.369 | wilson | |
| Risk in group 2 | 0.304 | 0.228 | 0.394 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0236 | -0.14 | 0.0935 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.922 | 0.616 | 1.38 | log | |
| Odds ratio, group 1 over group 2 | 0.892 | 0.505 | 1.58 | log | |
| Number needed to treat, for one fewer participant with the outcome on CD24Fc than on Placebo | 42.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | CD24Fc | Participants received single dose of CD24Fc 480 mg, diluted to 100 ml with normal saline, intravenous (IV) infusion in 60 minutes on Day 1. | 32 | 114 | OG000 |
| Group 2 | Placebo | Participants received single dose of placebo as normal saline solution 100 ml, IV infusion in 60 minutes on Day 1. | 35 | 115 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants Who Experience an Adverse Event (AE)
- Description
An AE was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, only AEs with Common Terminology Criteria for AE (CTACAE) grade ≥3 were included. The number of participants who experienced an AE were reported.
- Time frame
- Up to 30 days
- Population
- All randomized participants who received at least one dose of treatment.
Source ClinicalTrials.gov
Trial
- Title
- Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)
- NCT number
- NCT04317040
- Phases
- PHASE3
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- Efprezimod alfa, Placebo
- Lead sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Results first posted
- 2021-10-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04317040?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04317040-c31e40f2